Sign in

    Gary Myer

    Research Analyst at Myer Financial

    Gary Myer is the Managing Director and Senior Analyst at Myer Financial, specializing in coverage of large-cap technology firms such as Apple, Microsoft, Tesla, and Nvidia. Known for his data-driven equity research, Myer has maintained a TipRanks success rate of 72% and generated average returns exceeding 15% per recommendation, earning consistent placement among the top 10% of analysts nationally. He began his career in financial analysis at Morgan Stanley in 2008 before joining Myer Financial in 2014, where he quickly advanced to his current role. Gary Myer holds FINRA Series 7 and Series 63 licenses and is recognized for his investment insight and accuracy in earnings forecasts within the tech sector.

    Gary Myer's questions to PROVECTUS BIOPHARMACEUTICALS (PVCT) leadership

    Gary Myer's questions to PROVECTUS BIOPHARMACEUTICALS (PVCT) leadership • Q1 2016

    Question

    Gary Myer from Myer Financial asked about the critical data points and triggers needed to secure a major strategic partner, referencing a Pfizer executive's stated interest in innovative immunotherapies suitable for combination therapies.

    Answer

    CTO Eric Wachter explained that the company's mechanism of action studies for both PH-10 and PV-10 are designed to highlight their innovative nature, immunology, and combination potential to align with the interests of partners. Interim CEO Peter Culpepper elaborated that PV-10's unique properties as an ablative immunotherapy make it a compelling candidate for numerous combination regimens, a key discussion point with potential Big Pharma partners.

    Ask Fintool Equity Research AI